A phase II trial of gefitinib monotherapy in Chemotherapy-Naïve patients of 75 years or older with advanced non-small cell lung cancer

Journal of Thoracic Oncology

Volumn 3, Issue 10, 2008, Pages 1166-1171

  Ebi, Noriyuki ^a   Semba, Hiroshi ^b   Tokunaga, Sho J I ^c   Takayama, Koichi ^c   Wataya, Hiroshi ^d   Kuraki, Takashige ^e   Yamamoto, Hidehiko ^a   Akamine, Shin J I ^f   Okamoto, Isamu ^g   Nakanishi, Yoichi ^c  

^a ASO IIZUKA HOSPITAL   (Japan)

^b KUMAMOTO REGIONAL MEDICAL CENTER   (Japan)

^c KYUSHU UNIVERSITY   (Japan)

^d NATIONAL KYUSHU CANCER CENTER   (Japan)

^e FUKUOKA UNIVERSITY HOSPITAL   (Japan)

^f OITA PREFECTURAL HOSPITAL   (Japan)

^g KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Elderly; Gefitinib; Non small cell lung cancer

Indexed keywords

DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; GEMCITABINE; NAVELBINE; UFT; ANTINEOPLASTIC AGENT; QUINAZOLINE DERIVATIVE;

ACNE; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; CANCER PATIENT; CANCER TISSUE; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY SKIN; FATIGUE; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; HYPOXEMIA; INTERSTITIAL LUNG DISEASE; LIVER TOXICITY; LUNG ADENOCARCINOMA; LUNG CANCER SUBSCALE; LUNG NON SMALL CELL CANCER; MALE; MONOTHERAPY; MUCOSA INFLAMMATION; MULTICENTER STUDY; NAIL DISEASE; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; RASH; RATING SCALE; SURVIVAL RATE; SURVIVAL TIME; SYMPTOMATOLOGY; TREATMENT RESPONSE; VOMITING; ADENOCARCINOMA; CANCER STAGING; DRUG ANTAGONISM; GENETICS; HEALTH SURVEY; KAPLAN MEIER METHOD; LARGE CELL CARCINOMA; LUNG TUMOR; MAXIMUM TOLERATED DOSE; METASTASIS; PATHOLOGY; PROGNOSIS; QUALITY OF LIFE; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, LARGE CELL; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; FEMALE; HEALTH SURVEYS; HUMANS; KAPLAN-MEIERS ESTIMATE; LUNG NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; NEOPLASM STAGING; PROGNOSIS; QUALITY OF LIFE; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 58949088423     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e318186a88d     Document Type: Article

References (29)

1. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol 2001;2:533-543.
2. National Cancer Institute. Surveillance Epidemiology and End Results data. Web address available at: http://seer.cancer.gov/ (accessed December 20, 2007).
3. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. BMJ 1995;311: 899-909.
4. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med 2002;346:92-98.
5. Ohe Y, Ohashi Y, Kubota K, et al. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small cell lung cancer: four-arm cooperative study in Japan. Ann Oncol 2007;18: 317-323.
6. Aapro M, Extermann M, Repetto L. Evaluation of the elderly with cancer. Ann Oncol 2000;11(Suppl 3):223-229.
7. Balducci L, Extermann M. Cancer chemotherapy in the older patient. What the medical oncologist needs to know. Cancer 1997;80:1317-1322.
8. Langer CJ, Manola J, Bernardo P, et al. Cisplatin-based therapy for elderly patients with advanced non-small cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial. J Natl Cancer Inst 2002;94:173-181.
9. The Elderly Lung Cancer Vinorelbine Italian Study Group. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 1999;91:66-72.
10. Gridelli C, Perrone F, Gallo C, et al. Chemotherapy for elderly patients with advanced non small cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst 2003;95:362-372.
11. Barker AJ, Gibson KH, Grundy W, et al. Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer. Bioorg Med Chem Lett 2001;11:1911-1914.
12. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small cell lung cancer. J Clin Oncol 2003;46:2237-2246.
13. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer. JAMA 2003;290:2149-2158.
14. Cella DF, Bonomi AE, Lloyd SR, et al. Reliability and validity of the Functional Assessment of Cancer Therapy - Lung (FACT-L) quality of life instrument. Lung Cancer 1995;12:199-220.
15. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216.
16. National Cancer Institute. Common Toxicity Criteria (CTC) v2. 0. Web address available at: http://ctep.cancer.gov/reporting/ (accessed October 20, 2003).
17. Cella D, Herbst RS, Lynch TJ, et al. Clinically Meaningful Improvement in Symptoms and Quality of Life for Patients With Non-small Cell Lung Cancer Receiving Gefitinib in a Randomized Controlled Trial. J Clin Oncol 2005;23:2946-2954.
18. Kimura H, Kasahara K, Kawaishi M, et al. Detection of Epidermal Growth Factor Receptor Mutations in Serum as a Predictor of the Response to Gefitinib in Patients with Non-small Cell Lung Cancer. Clin Cancer Res 2006;12:3915-3921.
19. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
20. Zeger SL, Liang KY, Albert PS. Models for longitudinal data: a generalized estimating equation approach. Biometrics 1988;44:1049-1060.
21. Ando M, Okamoto I, Yamamoto N, et al. Predictive factors for interstitial lung disease, antitumor response, and survival in non-small cell lung cancer patients treated with gefitinib. J Clin Oncol 2006;24:2549-2556.
22. Lilenbaum R, Axelrod R, Thomas S, et al. Randomized phase II trial of erlotinib or standard chemotherapy in patients with advanced non-small cell lung cancer and a performance status of 2. J Clin Oncol 2006;26: 863-869.
23. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-2139.
24. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304: 1497-1500.
25. Inoue A, Suzuki T, Fukuhara T, et al. Prospective phase II study of gefitinib for chemotherapy- naïve patients with advanced non-small cell lung cancer with epidermal growth factor receptor gene mutations. J Clin Oncol 2006;24:3340-3346.
26. Niho S, Kubota K, Goto K, et al. First-line single agent treatment with gefitinib in patients with advanced non-small cell lung cancer: a phase II study. J Clin Oncol 2006;24:64-69.
27. Kudoh S, Takeda K, Nakagawa K, et al. Phase III Study of Docetaxel Compared With Vinorelbine in Elderly Patients With Advanced Non-small Cell Lung Cancer: results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904). J Clin Oncol 2006;24:3657-3663.
28. Douillard JY, Kim ES, Hirsh V, et al. Gefitinib (IRESSA) versus docetaxel in patients with locally advanced or metastatic non-small cell lung cancer pre-treated with platinum-based chemotherapy: a randomized, open-label Phase III study (INTEREST). J Thorac Oncol 2007;2: S305-S306.
29. Jackman DM, Yeap BY, Lindeman NI, et al. Phase II clinical trial of chemotherapy-naïive patients ≥70 years of age treated with erlotinib for advanced non-small cell lung cancer. J Clin Oncol 2007;25:760-766.